ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO956

Calculating Maximum Allowable Contrast Dose to Minimize Contrast Induced Nephropathy Following Coronary Angiography: Comparison of Validated Methods with Implications for Practice

Session Information

  • Patient Safety
    November 03, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Patient Safety

  • 1501 Patient Safety


  • Mawad, Habib, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
  • Zerr, Kelly M, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada
  • Singh, Anurag, BC Renal Agency, Vancouver, British Columbia, Canada
  • Robinson, Simon, Univ of British Columbia, Vancouver, British Columbia, Canada
  • Hardiman, Sean C, Cardiac Services BC, Vancouver, British Columbia, Canada
  • Levin, Adeera, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

The contrast volume used during angiographic procedures represents an important modifiable risk factor for contrast-induced nephropathy (CIN). As a result, attempts have been made to limit contrast exposure by determining maximum allowable contrast dose (MACD), using specific equations. Two published methods exist, but they use different components to derive the MACD: Method A uses weight and creatinine, Method B uses the estimated GFR (eGFR) multiplied by a specific ratio. Our study analyzed and compared the 2 methods with respect to concordance, and implications for incorporating into clinical practice. The goal was to find a simple equation to implement which would be safe (i.e. give the lowest MACD).


We calculated the MACD for a wide range of serum creatinine levels, weights and demographic variables (i.e. age, sex and race), using the 2 methods. Method A: MACD (mL) = (5* Body Weight (kg) * 88.42)/ Serum Creatinine (umol/L); and Method B: MACD (mL) = Ratio* eGFR (ml/min per 1.73m2). A ratio of 3 was used if eGFR >30 and a ratio of 2 if eGFR ≤30 ml/min per 1.73m2. Irrespective of methodology, recommendations suggest that MACD should not exceed 300 mL.


The results show a marked discordance in calculation of MACD depending on the equation used (see Figures). In the majority of cases method B gives a more conservative estimate of MACD. The difference is most marked for those who are heavier, older and are female, particularly non-black females.


Discrepancies in allowable contrast doses based on published formulae may lead to different and higher contrast exposure for some patients. We propose an alternative method which suggests lower contrast doses in those at highest risk of CIN. The impact of implementation of these methods on MACD used, subsequent incidence of CIN and dialysis as well as cardiovascular outcomes remains to be studied.